I missed this in the call yesterday from Dr Packham - interesting that they noticed a similar placebo issue in the FSGS trial.
“The potential for a legacy effect is intriguing, especially as early data analysis suggests a similar effect in the recently reported ACTION FSGS trial, and I look forward to the outcomes of the additional data analysis,” Packham said.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-217
-
- There are more pages in this discussion • 411 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |